Although the patient has not achieved normal vision, the world's first gene transplant for blindness, carried out by a British team, produced an unprecedented improvement in Steven Howarth's sight.
They injected genes only into Howarth's worst-affected eye and used the lowest dose in what they claim was strictly a safety trial.
"The evidence of his improvement is compelling. It is more than we could have expected at this stage of treatment," said Prof Robin Ali, who led the team at University College of London Institute of Ophthalmology and Moorfields Eye Hospital.
In fact, the student suffered from a genetic mutation, called Leber's congenital amaurosis which begins affecting the sight of sufferers in early childhood and eventually causes total blindness during a patient's twenties or thirties.
Currently, there is no treatment for the condition. Born with no peripheral or night vision, Howarth noticed a marked improvement after the two-hour operation. "Now, my sight when it's getting dark or it's badly lit is definitely better.
It's a small change
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
